Inovio Pharmaceuticals, INC. 8-K Filing
Ticker: INO · Form: 8-K · Filed: Dec 29, 2025 · CIK: 1055726
| Field | Detail |
|---|---|
| Company | Inovio Pharmaceuticals, INC. (INO) |
| Form Type | 8-K |
| Filed Date | Dec 29, 2025 |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Inovio Pharmaceuticals, INC. (ticker: INO) to the SEC on Dec 29, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (nge on which registered Common Stock, $0.001 par value INO The Nasdaq Stock Mark).
How long is this filing?
Inovio Pharmaceuticals, INC.'s 8-K filing is 3 pages with approximately 751 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 751 words · 3 min read · ~3 pages · Grade level 11.9 · Accepted 2025-12-29 08:20:19
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value INO The Nasdaq Stock Mark
Filing Documents
- d78035d8k.htm (8-K) — 27KB
- d78035dex991.htm (EX-99.1) — 15KB
- 0001193125-25-332322.txt ( ) — 161KB
- ino-20251229.xsd (EX-101.SCH) — 3KB
- ino-20251229_lab.xml (EX-101.LAB) — 18KB
- ino-20251229_pre.xml (EX-101.PRE) — 11KB
- d78035d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number 99.1 Press Release, dated December 29, 2025, "FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)." 104 Cover Page Interactive Data File (formatted as inline XBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INOVIO PHARMACEUTICALS, INC. Date: December 29, 2025 By: /s/ Peter Kies Peter Kies Chief Financial Officer